Reuters on MSN1mon
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued ...
MarketWatch1mon
GSK settles vast majority of Zantac claims for $2.2 billion
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...
pharmaphorum4d
GSK goes all-in on CureVac’s mRNA vaccines
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...
pharmaphorum2d
GSK says Nucala hits the target in new COPD trial
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
Seeking Alpha1mon
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 ...
FierceBiotech28d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...
Yahoo Finance28d
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...
STAT12d
Sales of GSK’s RSV vaccine down dramatically from last year
LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...
FierceBiotech26d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...
Reuters1mon
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...
Los Angeles Daily News1mon
GSK to settle 80,000 Zantac cases for up to $2.2 billion
GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen ...